All In MedTech

Device Trial Radar · NCT05496998

Transcatheter Mitral Valve Replacement in Patients With Severe Symptomatic Mitral Regurgitation - APOLLO-EU Trial

Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR Transfemoral System in Patients With Severe Symptomatic Mitral Regurgitation - APOLLO-EU Trial

Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Feb 7, 2023

Primary completion

Aug 2029

Study completion Dec 2038

Sponsor

Lead sponsor
Medtronic CardiovascularPublic (MDT)
Sponsor type
Industry
First posted
Aug 11, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluate the safety and efficacy of Medtronic Intrepid™ TMVR TF System in patients with moderate-to-severe or severe symptomatic mitral regurgitation, or moderate symptomatic mitral regurgitation combined with mitral stenosis in the presence of MAC who, by agreement of the local site multidisciplinary heart team experienced in mitral valve therapies, are unsuitable for treatment with approved transcatheter repair or surgical mitral valve intervention.

Conditions

  • Mitral Regurgitation

Interventions

  • Medtronic Intrepid™ TMVR TF SystemDevice

    Patients with moderate-to-severe or severe symptomatic mitral regurgitation, or moderate symptomatic mitral regurgitation combined with mitral stenosis in the presence of MAC will have a Transcatheter Mitral Valve Replacement with the Medtronic Intrepid™ TMVR Transfemoral System

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety: all-cause mortality at 1-year post-procedure.Time frame: 1 year
  2. Efficacy: Percentage of subjects with none/trace or mild mitral regurgitation at 30 days post-procedure.Time frame: 30 days

Locations

38 sites in 8 countries. Site status is shown where the registry gives one.

  • Aarhus University Hospital

    Aarhus, Denmark · Recruiting

  • Rigshospitalet

    Copenhagen, Denmark · Recruiting

  • Odense University Hospital

    Odense, Denmark · Recruiting

35 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.